Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.56 |
| ▸ | NPC1 | O15118 | 6/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.55 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.55 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.55 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.48 |
| ▸ | RELA | Q04206 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13799142 | 0.91 | LMNA (0.47) | RAB9ANPC1SMN1; SMN2NPSR1PDK1 | |
| SCHEMBL2880191 | 0.87 | LMNA (0.54) | RAB9ANPC1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL28220374 | 0.85 | RXFP1 (0.47) | RAB9ANPC1SMN1; SMN2NPSR1PDK1 | |
| SCHEMBL4725312 | 0.85 | SMN1; SMN2 (0.52) | RAB9ANPC1SMN1; SMN2NPSR1PDK1 | |
| SCHEMBL24427984 | 0.84 | CXCR2 (0.48) | RAB9ANPC1NPSR1PDK1PDK2 | |
| SCHEMBL22874399 | 0.84 | HDAC1 (0.50) | RAB9ANPC1SMN1; SMN2NPSR1PDK1 | |
| SCHEMBL4365913 | 0.83 | GAA (0.53) | RAB9ANPC1SMN1; SMN2NPSR1PDK1 | |
| SCHEMBL29353000 | 0.83 | HDAC1 (0.52) | RAB9ANPC1LMNAPOLBRXFP1 | |
| SCHEMBL211033 | 0.83 | HDAC1 (0.52) | RAB9ANPC1LMNAPOLBRXFP1 | |
| SCHEMBL513736 | 0.82 | RAB9A (0.64) | RAB9ANPC1SMN1; SMN2NPSR1PDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112341352-A | Preparation method of flurbiprofen | 浙江东亚药业股份有限公司 | 2021-02-09 | — | — | CN | claimed |
| CN-103275112-A | Method for continuously synthesizing arylboronic acid ester by utilizing microreactor | JINAN SHAOYUAN MEDICAL TECHNOLOGY CO LTD | 2013-09-04 | — | — | CN | claimed |
| CN-118186412-A | Method for electrochemically synthesizing p-hydroxyphenylamide compound and application thereof | 无锡绿能电合科技有限公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-116804009-A | Intermediate for synthesizing TGF-beta inhibitor and method for preparing TGF-beta inhibitor by using intermediate | 株式会社麦迪帕克特 | 2023-09-26 | — | — | CN | disclosed |
| US-20230130739-A1 | DEUTERATED sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2023-04-27 | — | — | US | disclosed |
| US-11332416-B2 | Process for synthesizing fluorinated cyclic aliphatic compounds | Westfälische Wilhelms-Universität Münster (DE) | 2022-05-17 | — | — | US | disclosed |
| WO-2022006340-A1 | ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. (US) | 2022-01-06 | — | — | WO | disclosed |
| WO-2022006340-A1 | ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. (US) | 2022-01-06 | — | — | WO | disclosed |
| EP-3237385-B1 | MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER | US HEALTH (US) | 2021-11-24 | — | — | EP | disclosed |
| CN-108002976-B | Preparation method of 1-fluoro-2-bromo-3-iodobenzene | 金凯(辽宁)生命科技股份有限公司 | 2021-04-23 | — | — | CN | disclosed |
| WO-2021072330-A1 | GALNAC-TGFBR1 INHIBITOR CONJUGATES FOR THE TREATMENT OF LIVER DISEASES | SILVERBACK THERAPEUTICS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| EP-0142152-B1 | Novel substituted 1,2,4-triazolo- [1,5-a] pyrimidine-2-sulfonamides and compositions and methods of controlling undesired vegetation and suppressing the nitrification of ammonium nitrogen in soil | THE DOW CHEMICAL COMPANY (US) | 1991-03-20 | — | — | EP | disclosed |
| US-4954163-A | PRE-AND POSTEMERGENCE HERBICIDES | THE DOW CHEMICAL COMPANY (US) | 1990-09-04 | — | — | US | disclosed |
| US-4886883-A | HERBICIDES | THE DOW CHEMICAL COMPANY (US) | 1989-12-12 | — | — | US | disclosed |
| EP-0330137-A1 | Intermediate compounds for the preparation of 1,2,4-triazolo [1,5-a]pyrimidine-2-sulfonamides | DowElanco (US) | 1989-08-30 | — | — | EP | disclosed |
| US-4818273-A | Substituted 1,2,4-triazolo[1,5-a]pyrimidine-2-sulfonamides, compositions containing them, and their utility as herbicides | THE DOW CHEMICAL COMPANY (US) | 1989-04-04 | — | — | US | disclosed |
| US-4755212-A | Novel substituted 1,2,4-triazolo[1,5-a]pyrimidine-2-sulfonamides and compositions and method for inhibiting pollen formation in corn | THE DOW CHEMICAL COMPANY (US) | 1988-07-05 | — | — | US | disclosed |
| US-4741764-A | SUPPRESSION OF NITRIFICATION OF AMMONIUM NITROGEN IN THE SOIL | THE DOW CHEMICAL COMPANY (US) | 1988-05-03 | — | — | US | disclosed |
| US-4740233-A | Substituted 1,2,4-triazolo[1,5-a]-pyrimidine-2-sulfonamides and compositions and methods of controlling undesired vegetation and suppressing the nitrification of ammonium nitrogen in soil | THE DOW CHEMICAL COMPANY (US) | 1988-04-26 | — | — | US | disclosed |
| EP-0142152-A2 | Novel substituted 1,2,4-triazolo- [1,5-a] pyrimidine-2-sulfonamides and compositions and methods of controlling undesired vegetation and suppressing the nitrification of ammonium nitrogen in soil | THE DOW CHEMICAL COMPANY (US) | 1985-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11332416-B2 | Process for synthesizing fluorinated cyclic aliphatic compounds | HRH4, HRH1, AHR | RAB9A 937/4885NPC1 974/4885SMN1; SMN2 4460/4885 |
| US-20230130739-A1 | DEUTERATED sGC STIMULATORS | PDE2A, GUCY1A2, PDE3A | RAB9A 924/4885NPC1 3188/4885SMN1; SMN2 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.